CXCL10 and COVID-19: While TRAMs from patients with moderate COVID-19 integrated with TRAMs from control lung tissue, they did not mix with normal TRAMs completely, as they were activated and characterized by increased expression of IFI27 and CXCL10. MoAMs are predominantly found in samples from patients with severe COVID-19 and to a lesser extent in samples from patients with moderate COVID-19.